|
News FDA Approves Baxter`s ADVATE as the Only FVIII for Routine Prophylaxis in Both Adults and Children with Hemophilia A
Baxter International Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method] for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A. |
|
News Biogen Idec and Swedish Orphan Biovitrum Present Data on Long-Lasting Recombinant Factor VIII Therapy at International Society on Thrombosis and Haemostasis Meeting
Biogen Idec and Swedish Orphan Biovitrum announced Phase 1/2a trial data showing that the companies` long-lasting fully-recombinant factor VIII Fc fusion protein (rFVIIIFc) was well tolerated and demonstrated an approximately 1.7-fold increase in half-life compared with Advate |
|
News Biogen Idec and Swedish Orphan Biovitrum Announce First Patient Dosed in Global Registrational Trial of Long-Lasting Recombinant Factor VIII Fc Fusion Protein
Biogen Idec and Swedish Orphan Biovitrum announced that the first patient has been dosed with the companies` long-lasting recombinant Factor VIII Fc fusion protein (rFVIIIFc) in a global registrational clinical trial. |